Navigation Links
Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
Date:8/6/2008

s early as two minutes after dosing with AZ-007. There were no serious adverse events. The most frequently reported adverse events in subjects receiving AZ-007 were dizziness and somnolence. These data indicate a rapid onset of effect, apparently directly related to the IV-like pharmacokinetics, and showed that AZ-007 was generally safe and well tolerated in this population of healthy volunteers.

Conference Call Information

Alexza will host a conference call tomorrow morning, Thursday, August 7, 2008 at 8:45 a.m. Eastern Time. A replay of the call will be available for two weeks following the event. The conference call, replay and webcast are open to all interested parties.

To access the conference call via the Internet, go to http://www.alexza.com, under the "Investor Relations" link. Please join the call at least 15 minutes prior to the start of the call to ensure time for any software downloads that may be required. Interested parties may also pre-register to avoid pre-call delays at https://www.theconferencingservice.com/prereg/key.process?key=PHY9DE66U.

To access the live conference call via phone, dial 888-680-0894. International callers may access the live call by dialing 617-213-4860. The reference number to enter the call is 37382979.

The replay of the conference call may be accessed via the Internet, at http://www.alexza.com, or via phone at 888-286-8010 for domestic callers or 617-801-6888 for international callers. The reference number for the replay of the call is 47372481.

About Alexza Pharmaceuticals

Alexza Pharmaceuticals is an emerging specialty pharmaceutical company focused on the development and commercialization of novel, proprietary products for the treatment of acute and intermittent conditions. The
'/>"/>

SOURCE Alexza Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Alexza Completes Target Enrollment in AZ-104 Phase 2a Clinical Trial in Migraine Patients
2. Alexza Initiates AZ-007 (Staccato(R) Zaleplon) Phase 1 Clinical Trial and Updates Clinical Pipeline Development Status
3. Alexzas AZ-104 (Staccato(R) Loxapine) Phase 2a Trial Meets Primary Endpoint of 2-Hour Pain Relief in Patients with Migraine Headache
4. Alexza Reports 2007 Year-End Financial Results and Updates Clinical Pipeline Status
5. Alexza Announces Positive Phase 1 Results With AZ-007 (Staccato(R) Zaleplon)
6. Alexza Completes Enrollment in Phase 2a Clinical Trial With AZ-002 (Staccato(R) Alprazolam) in Panic Disorder Patients
7. Alexza Pharmaceuticals to Present AZ-004 Phase 2a Clinical Data at the American Psychiatric Association Annual Meeting
8. Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder
9. Alexza Completes Enrollment in Phase 3 Clinical Trial with AZ-004 (Staccato(R) Loxapine) for Acute Agitation
10. Alexza Pharmaceuticals to Present AZ-104 Phase 2a Clinical Data at the American Headache Society Annual Scientific Meeting
11. Alexza Initiates Second Phase 3 Clinical Trial for AZ-004 (Staccato(R) Loxapine)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... , Sept. 17, 2014   GS1 US ... to implement GS1 Standards to support the 2013 ... patient safety and security in the pharmaceutical supply ... Standards to U.S. Pharmaceutical Supply Chain Business Processes ... , was developed in collaboration with GS1 ...
(Date:9/17/2014)... Calif. , Sept. 17, 2014 ... announced that it has earned a $4 million ... AKAO ) associated with the initiation of a ... serious multi-drug resistant (MDR), gram-negative bacterial infections.  The ... study to evaluate the efficacy and safety of ...
(Date:9/17/2014)... Sept. 17, 2014 Sutro Biopharma, a biopharmaceutical ... the biopharmaceutical division of Merck KGaA, Darmstadt, ... the United States and ... license agreement to develop antibody drug conjugates (ADCs). ADCs ... drug. The antibody is thought to specifically target and ...
Breaking Medicine Technology:New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 2Isis Pharmaceuticals Earns $4 Million from Achaogen for the Initiation of a Phase 3 Study of Plazomicin 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... Nov. 2, 2010 GeNO LLC ( www.genollc.com ... announced today that it has submitted an Investigational ... and Drug Administration (FDA) for the GeNO NITROsyl ... pulmonary hypertension in patients with pulmonary arterial hypertension ...
... , a drug research and development company focused on the ... awarded a grant by the United States government under the ... of its lead product CM-AT for autism.  CM-AT is presently ... US. The QTDP grant program provides support for ...
Cached Medicine Technology:GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension 2GeNO LLC Submits Investigational New Drug Application for Its NITROsyl™ Inhaled Nitric Oxide System to Treat Chronic Pulmonary Hypertension 3Curemark Awarded Qualifying Therapeutic Discovery Project (QTDP) Grant 2
(Date:9/17/2014)... New York, New York (PRWEB) September 17, 2014 ... ) filings involving the Conserve line of metal-on-metal ... litigation now underway in U.S. District Court, Northern ... to an updated Case List issued by the ... 15, 2014, at least 397 product liability claims ...
(Date:9/17/2014)... September 17, 2014 Boston Children’s ... create a monthly concert series, introducing young Museum ... the Top, America’s premier national platform celebrating the ... Many of the young musicians featured will also ... “Boston Children’s Museum is fortunate to partner with ...
(Date:9/17/2014)... 2014 Smart Flour Foods™ has been ... Grocer, a leading trade magazine targeted toward food retailers. ... and flavor, among other attributes. Smart Flour Foods’ Uncured ... in the September print issue of Progressive Grocer as ... pizza won based on its superior performance in the ...
(Date:9/17/2014)... Palo Alto, CA (PRWEB) September 17, 2014 ... with Stanford University, revealed 12 companies raising rounds of ... attended by a few hundred investors and media, was ... square foot headquarters located next to the university. The ... staff and volunteers, adjacent to StartX-QB3 Labs, a 2,000 ...
(Date:9/17/2014)... GA (PRWEB) September 17, 2014 Leading ... to announce the launch of its new vegan and ... is extremely effective and provided the results skincare testers ... to create a gentle yet active mask that provided ... Lake Louise.” , This Sugar Cane Fruit Mask combines ...
Breaking Medicine News(10 mins):Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 2Health News:Wright Hip Lawsuit News: Nearly 400 Filings Reported in Federal Wright Conserve Hip Replacement Litigation, Bernstein Liebhard LLP Reports 3Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 2Health News:Boston Children's Museum Partners with From the Top to Offer Monthly Concert Series 3Health News:Smart Flour Foods Wins 2014 Progressive Grocer Editor’s Pick Award 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 2Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 3Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 4Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 5Health News:Stanford-affiliated StartX Showcases Startups, New HQ, and Growth of Stanford-StartX Fund 6Health News:EcoBeauty Brand Lotus Moon Unveils New Gluten-Free Sugar Cane Fruit Mask 2
... doing away with the user charges imposed on patients at ... senior CPI(M) MP said today. ,This was conveyed to ... Basudeb Acharia when they called on Prime Minister Manmohan Singh ... Nirmala Deshpande and Hannan Mollah, met the Prime Minister weeks ...
... next week to repair a tennis elbow injury that has ... African vice-captain was forced out of last year's tour of ... the tour of Sri Lanka in August., ,'However, he ... in India in September and the 2007 World Cup in ...
... Intelligence arrested three persons, including the Managing Director ... alleged illegal export of Ephedrine tablets, a controlled ... Substances (NDPS) Act, 1985. ,According to ... persons have been remanded to judicial custody by ...
... by the Johns Hopkins researchers it is found that ... brain which controls// the muscle movements is responsible for ... research is Professor Reza Shadmehr and he and his ... PLoS Biology. This study would help to change the ...
... Royal Brisbane and Women's Hospital (RBWH), Sydney struggles with ... in three wards were found with a bacterium ... skin. ,To prevent the spread, 12 patients ... cent burns) were shifted to Sydney hospital and some ...
... the city, joined by members of Medical Representatives Association ... protest the Centre's reservation// proposals, affecting heatlh services in ... a number of women and ayurvedic doctors, also took ... to Prime Minister Manmohan Singh to the Deputy Commissioner, ...
Cached Medicine News:
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: